- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.11. | Hedge Fund and Insider Trading News: Bill Ackman, Steve Cohen, Glen Kacher, MAIA Biotechnology Inc (MAIA), SolarWinds Corp (SWI), and More | 5 | Insider Monkey | ||
| 05.11. | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11. | Maia Biotechnology-Direktor Stan Smith erwirbt Aktien im Wert von 250.999 US-Dollar | 2 | Investing.com Deutsch | ||
| 29.10. | MAIA Biotechnology prices $2.44M private placement | 2 | Seeking Alpha | ||
| 15.10. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics | 170 | Business Wire | MAIA seeks to advance two new THIO-derived telomere-targeting molecules to clinical trials MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| 10.09. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.08. | MAIA Biotechnology, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 23.07. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| MAIA BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 23.07. | MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients | 1 | Benzinga.com | ||
| 23.07. | MAIA Biotech Reports Positive Phase 2 Data For THIO With Cemiplimab In Non-Small Cell Lung Cancer | 1 | RTTNews | ||
| 06.06. | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.06. | MAIA Biotech's Phase 2 THIO-101 Study Shows Positive Results In Non-Small Cell Lung Cancer | 4 | RTTNews | ||
| 29.05. | MAIA Biotechnology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.02. | MAIA Biotechnology, Inc.: MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer | 536 | GlobeNewswire (Europe) | Topline data expected in second half of 2024THIO-101 will be the first completed clinical study of a telomere targeting agent in the field of cancer drug discovery and treatment CHICAGO, IL, Feb.... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 84,39 | +0,36 % | Gilead's Livdelzi Shows Sustained Efficacy, Long-Term Safety In PBC Management | FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% of participants with... ► Artikel lesen | |
| ABBVIE | 159,82 | +0,43 % | European Commission Approves AbbVie's ELAHERE For Platinum-Resistant Ovarian Cancer Treatment | WASHINGTON (dpa-AFX) - AbbVie (ABBV) announced that the European Commission approved ELAHERE or mirvetuximab soravtansine for the treatment of adult patients with folate receptor-alpha (FR?)... ► Artikel lesen | |
| ABBOTT LABORATORIES | 109,78 | -0,20 % | Insulet Says Omnipod 5 AID System Now Compatible With Abbott's FreeStyle Libre 2 Plus CGM Sensor | NORTH CHICAGO (dpa-AFX) - Insulet Corp. (PODD), a provider of tubeless insulin pump technology, announced Wednesday that the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 65,86 | -0,17 % | Edwards Lifesciences-Aktie legt um 4,75 Prozent zu (67,0318 €) | Der Anteilsschein von Edwards Lifesciences notiert am Montag fester. Das Papier notiert aktuell bei 70,98 US-Dollar. Eine Verteuerung in Höhe von 3,22 US-Dollar erfreut derzeit die Aktionäre von Edwards... ► Artikel lesen | |
| SCHOTT PHARMA | 26,220 | -0,38 % | EQS-AFR: SCHOTT Pharma AG & Co. KGaA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: SCHOTT Pharma AG & Co. KGaA
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
SCHOTT Pharma AG & Co. KGaA:... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 14,200 | -0,35 % | Assembly Biosciences - Herpes-Wirkstoff übertrifft Erwartungen | Mein diesjähriger Top-Favorit Assembly Biosciences (WKN: A402CB) präsentierte gestern herausragende Studiendaten seines Wirkstoffkandidaten ABI-5366 zur Behandlung von wiederkehrendem Genitalherpes.... ► Artikel lesen | |
| CASSAVA SCIENCES | 25,340 | +2,47 % | Cassava Sciences, Inc.: Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer | ||
| PENTIXAPHARM | 3,180 | +2,25 % | EQS-News: Pentixapharm Holding AG: Erster Patient in Phase I/II Studie zu akuter myeloischer und akuter lymphoblastischer Leukämie mit Lu177-PentixaTher behandelt, Stärkung der Datenlage für gezielte Radiotherapie | EQS-News: Pentixapharm Holding AG
/ Schlagwort(e): Studie
Erster Patient in Phase I/II Studie zu akuter myeloischer und akuter lymphoblastischer Leukämie mit Lu177-PentixaTher... ► Artikel lesen | |
| ZEALAND PHARMA | 94,70 | -0,63 % | Zealand Pharma A/S: Zealand Pharma Announces Financial Results for the First Nine Months of 2024 | Company announcement - No. 49 / 2024 Zealand Pharma Announces Financial Results for the First Nine Months of 2024 Continued strong progress across obesity pipeline with proprietary assets ready for... ► Artikel lesen | |
| EXSCIENTIA | 4,520 | -1,74 % | XFRA 0RK: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEXSCIENTIA SP.ADRS... ► Artikel lesen | |
| UNITED THERAPEUTICS | 347,30 | +0,49 % | Empowered Funds LLC Lowers Holdings in United Therapeutics Co. (NASDAQ:UTHR) | ||
| TG THERAPEUTICS | 30,300 | +2,43 % | TG Therapeutics, Inc.: New Data for BRIUMVI (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment | During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained consistent... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 297,50 | -1,20 % | Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra | ||
| KALA BIO | 6,200 | -0,40 % | KALA BIO, Inc. - 10-Q, Quarterly Report | ||
| BRIDGEBIO PHARMA | 22,180 | +1,42 % | BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market |
MAIA BIOTECHNOLOGY INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,285 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAIA BIOTECHNOLOGY INC finden Sie auf Wallstreet Online.
